Activated hepatitis B surface antigen product.

摘要

A vaccine containing an activated HBs antigen product, originally isolated from human HBsAg containing plasma, prepared synthetically, or by DNA recombinant techniques and containing 0.1-99.5% of other proteins from human and/or animal origin based on the total amount of protein material in the vaccine, not being added anti-HBs antibodies, in which the HBs Ag particles are aggregated to agglomerates having a thickness of 18-22 nanometers and a length of 36 nanometers at a minimum or in which vaccine the single HBsAg particles are complexed with plasma proteins of human or animal origin.